Analyst Expectations for Axsome Therapeutics's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, Axsome Therapeutics (NASDAQ:AXSM) received mostly bullish analyst ratings, with an average 12-month price target of $125.4, up 17.75% from the previous average of $106.50.
June 12, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received mostly bullish analyst ratings in the last quarter, with an increased average 12-month price target of $125.4.
The majority of analyst ratings for Axsome Therapeutics are bullish, indicating a positive outlook for the stock. The increased average 12-month price target of $125.4, up 17.75% from the previous average, suggests that analysts expect the stock price to rise in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100